Title for MeetingAbstracts
Alphabetical listing of titles
PHENOTYPIC EVOLUTION OF ATTENUATED, DUAL TROPIC HIV-1, HARBOURED BY THE COMMON DONOR OF THE SYDNEY BLOOD BANK COHORT OF LONG TERM SURVIVORS.
Phenotypic expressions of CCR5-delta 2/delta 32 homozygosity.
Phenotypic heterogeneity between peripheral blood (PB) and lymph node (LN) HIV isolates.
Phenotypic HIV resistance in vitro correlates with viral load response to abacavir (1592, ABC) in vivo.
Phenotypic identification of CD4 and CD8 cytotoxic T lymphocytes in TCR V beta expansions in primary HIV-1 infection.
Phenotypic markers of immune activation in rhesus monkeys infected with SIV.
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT).
Phenotypic modulations of H9 T cells infected either with HTLV-I, HIV-1 or doubly infected.
Phenotypic profile of HIV lymph nodes and tonsils using quantitative image analysis.
Phenotypic Profiling of Third-Generation Cephalosporins: Impact on Screening for Putative Extended-Spectrum beta-Lactamases in E. coli and K. pneumoniae.
Phenotypic Resistance and Prevalence of Specific Nucleoside Analog Mutation Combinations (NAMs) in Reverse Transcriptase in a Dataset of Recent HIV-1 Clinical Isolates.
Phenotypic resistance and virologic responses to indinavir (IDV) 800 mg-ritonavir (RTV) 200 mg bid-based salvage regimens in patients with prior protease inhibitor (PI) failures.
Phenotypic resistance testing for RT inhibitors with a biochemical method - problems and potential solutions.
Phenotypic resistance testing significantly improves response to therapy: a randomized trial (VIRA3001).
Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001).
Phenotypic Resistance to Protease Inhibitors Predicts Outcome of a Five Drug Combination Including Ritonavir, Saquinavir and Efavirenz in Patients Who Failed on HAART.
Phenotypic sensitivity of HIV-1 viral isolates during combination delavirdine + zidovudine therapy.
Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral load response.
Phenotypic susceptibility and virologic responses in nucleoside reverse transcriptase inhibitor (NRTI)-experienced subjects receiving NRTIS + efavirenz (EFV), nelfinavir (NFV), or both in ACTG 364.
Phenotypic susceptibility of HIV-1 RT containing substitutions which engender resistance to nucleoside and nonnucleoside inhibitors.
Phenotypic Susceptibility to Adefovir Dipivoxil in Clinical Samples with Defined RT Genotypic Resistance Patterns.
Phenotypic susceptibility to non-nucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
Phenotypic switching in Cryptococcus neoformans strain 24067A.
Phenotypic switching in Cryptococcus neoformans.
Phenotypic variation in HIV-1 NEF demonstrated with a panel of epitope specific monoclonal antibodies.
Phenotypic zidovudine (ZDV) resistance and perinatal HIV-1 transmission.
Phenotypical and histological patterns of lymphomas in HIV-patients before and after HAART.
Phenotypical differences in clinical HIV/AIDS disease with Thailand HIV-1 genotypes A and B.
Phenyl-Thiazolylurea-Sulfonamides as Novel Inhibitors of Phenylalanine-tRNA Synthetase.
Phenytoin (PH) monitoring in HIV(+) individuals: is there an interaction with zidovudine (ZDV)?